Molecure Announces Details for Virtual R&D Day Webcast to be held on Wednesday 7th December 2022
Retrieved on:
måndag, december 5, 2022
Sarcoidosis, Laboratory, Degenerative disease, Idiopathic pulmonary fibrosis, Cell biology, Flemish Institute for Technological Research, University, Rutgers University, Warsaw Stock Exchange, VIB, Yale University, Patient, ARG1, Cancer, Biology, ARG2, International Institute for Nanotechnology, RNA, MOC, Pharmaceutical industry
Molecure's most advanced in-house drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of interstitial lung diseases, such as sarcoidosis and idiopathic pulmonary fibrosis, that is Phase II ready.
Key Points:
- Molecure's most advanced in-house drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of interstitial lung diseases, such as sarcoidosis and idiopathic pulmonary fibrosis, that is Phase II ready.
- A Phase II trial in patients with sarcoidosis is expected to start in 2023.
- Our second proprietary candidate is OATD-02, an oral, potent and selective first-in-class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer.
- Molecure's headquarters and laboratories are located in Warsaw, Poland with an additional laboratory facility in d. The company is listed on the Warsaw Stock Exchange (ticker: MOC).